Roger Bullock

Roger Bullock

UNVERIFIED PROFILE

Are you Roger Bullock?   Register this Author

Register author
Roger Bullock

Roger Bullock

Publications by authors named "Roger Bullock"

Are you Roger Bullock?   Register this Author

63Publications

993Reads

26Profile Views

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

N Engl J Med 2018 01;378(4):321-330

From the Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III-Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC - both in Australia (M.W.); Fundació ACE, Alzheimer Research Center and Memory Clinic, Institut Català de Neurociències Aplicades, Barcelona (M. Boada); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (R.B.); the Division of Geriatric Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (M. Borrie); Clinic for Medicine of the Elderly, Diakovere Henriettenstift, Hannover, Germany (K.H.); Karolinska Institutet Alzheimer's Disease Research Center and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden (N.A.); the Department of Pathophysiology and Transplantation, Neurology Unit, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan (E. Scarpini); Eli Lilly (H.L.-S., M.C., A.H., K.S., V.P.H., C.C., R.K., M.M., R.D., K.J.S., E. Siemers) and the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine (R.A.D.) - both in Indianapolis; and Avid Radiopharmaceuticals, Philadelphia (M.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1705971DOI Listing
January 2018

Statins for the prevention of dementia.

Cochrane Database Syst Rev 2016 Jan 4(1):CD003160. Epub 2016 Jan 4.

Centre for Public Health, Queen's University Belfast, Institute of Clinical Sciences, Block B, Grosvenor Road, Belfast, Co Antrim, UK, BT12 6BA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD003160.pub3DOI Listing
January 2016

Incidence of stroke and seizure in Alzheimer's disease dementia.

Age Ageing 2015 Jul 24;44(4):695-9. Epub 2015 May 24.

Janssen Research and Development, LLC, South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ageing/afv061DOI Listing
July 2015

Statins for the treatment of dementia.

Cochrane Database Syst Rev 2014 Jul 8(7):CD007514. Epub 2014 Jul 8.

Department of Geriatric Medicine, Belfast Health and Social Care Trust, Lisburn Road, Belfast, Co Antrim, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD007514.pub3DOI Listing
July 2014

A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Prim Care Companion CNS Disord 2013 7;15(2). Epub 2013 Mar 7.

Alzheimer Neurobiology Center, Karolinska Institute, Stockholm, Sweden (Drs Nordberg and Darreh-Shori); Wolfson Centre for Age-Related Diseases, King's College, London, United Kingdom (Dr Ballard); Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom (Dr Bullock); and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Dr Somogyi).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.12r01412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733526PMC
August 2013

Cochrane review on 'Statins for the treatment of dementia'.

Int J Geriatr Psychiatry 2013 Feb 2;28(2):119-26. Epub 2012 Apr 2.

School of Medicine, National University of Ireland, Galway, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gps.3797DOI Listing
February 2013

A welcome from the new editor.

Authors:
Roger Bullock

Curr Ther Res Clin Exp 2012 Jun;73(3):85

Victoria Centre, Swindon, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.curtheres.2012.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954006PMC
June 2012

Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease.

Alzheimers Dement 2011 Mar 5;7(2):177-84. Epub 2010 Nov 5.

UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2010.03.016DOI Listing
March 2011

Hip fracture risk and subsequent mortality among Alzheimer's disease patients in the United Kingdom, 1988-2007.

Age Ageing 2011 Jan 18;40(1):49-54. Epub 2010 Nov 18.

Wyeth, a Pfizer Company-Epidemiology, Collegeville, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ageing/afq146DOI Listing
January 2011

Statins for the treatment of dementia.

Cochrane Database Syst Rev 2010 Aug 4(8):CD007514. Epub 2010 Aug 4.

Department of Geriatric Medicine, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, UK, BT9 7BL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD007514.pub2DOI Listing
August 2010

Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future.

Int J Alzheimers Dis 2009 Dec 22;2009. Epub 2009 Dec 22.

Department of Psychiatry and Human Behavior, UCI Neuropsychiatric Center, Irvine School of Medicine, University of California, 101 the City Drive South, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4061/2009/949271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925210PMC
December 2009

Cholinesterase inhibition: is there evidence for disease-modifying effects?

Curr Med Res Opin 2009 Oct;25(10):2439-46

Clinical Neuroscience Centre, University of Hull, Hull HU6 7RX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/03007990903209332DOI Listing
October 2009

Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia.

Cochrane Database Syst Rev 2009 Oct 7(4):CD004034. Epub 2009 Oct 7.

Department of Geriatric Medicine, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, UK, BT9 7BL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD004034.pub3DOI Listing
October 2009

Statins for the prevention of dementia.

Cochrane Database Syst Rev 2009 Apr 15(2):CD003160. Epub 2009 Apr 15.

Department of Geriatric Medicine, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, UK, BT9 7BL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD003160.pub2DOI Listing
April 2009

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

Lancet 2008 Jul;372(9634):216-23

Division of Clinical Neurosciences, University of Southampton, Southampton, UK; Moorgreen Hospital, Hampshire Partnership Trust, Southampton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(08)61075-2DOI Listing
July 2008

Donepezil for the treatment of agitation in Alzheimer's disease.

N Engl J Med 2007 Oct;357(14):1382-92

Medical Research Council Neurogeneration Research Centre, Institute of Psychiatry, King's College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa066583DOI Listing
October 2007

Can we afford not to have integrated dementia services?

Age Ageing 2007 Jul 11;36(4):357-8. Epub 2007 Jun 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ageing/afm071DOI Listing
July 2007

Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.

Curr Alzheimer Res 2007 Jul;4(3):277-93

Kingshill Research Centre, Swindon, UK.

View Article

Download full-text PDF

Source
July 2007

Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.

Authors:
Roger Bullock

Alzheimer Dis Assoc Disord 2006 Jan-Mar;20(1):23-9

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.wad.0000201847.29836.a5DOI Listing
July 2006

Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants.

Int Psychogeriatr 2006 Mar 11;18(1):151-62. Epub 2006 Jan 11.

The MEDTAP Institute at UBC, Bethesda, MD 20814, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1041610205002450DOI Listing
March 2006

Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.

Eur Psychiatry 2005 Nov 27;20(7):490-6. Epub 2005 Jan 27.

Centre Mémoire de Ressources & de Recherche, CHU, Hopital Pasteur, Université de Nice-Sophia Antipolis, 30, Avenue de la Voie Romaine, 06002 Nice cedex 1, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eurpsy.2004.09.031DOI Listing
November 2005

Executive function: the core feature of dementia?

Dement Geriatr Cogn Disord 2004 21;18(2):207-16. Epub 2004 Jun 21.

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000079202DOI Listing
February 2005

Prediction of the rate of decline in cognitive function in Alzheimer's disease: a correction.

Dement Geriatr Cogn Disord 2004 ;18(3-4):349-50

HPRU Medical Research Centre, University of Surrey, Guildford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000080171DOI Listing
February 2005

SGS-742 Novartis.

Authors:
Roger Bullock

Curr Opin Investig Drugs 2005 Jan;6(1):108-13

The Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
January 2005

Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings.

Authors:
Roger Bullock

Curr Med Res Opin 2005 Jan;21(1):1-10

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079904x16777DOI Listing
January 2005

Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia.

J Neurol Sci 2004 Nov;226(1-2):81-7

Department of Medicine/Neurology, University of Texas HSC at San Antonio and the Audie Murphy Veterans Administration Hospital, Mail Code 7883, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0022510X0400299
Publisher Site
http://dx.doi.org/10.1016/j.jns.2004.09.016DOI Listing
November 2004

The needs of the caregiver in the long-term treatment of Alzheimer disease.

Authors:
Roger Bullock

Alzheimer Dis Assoc Disord 2004 Apr-Jun;18 Suppl 1:S17-23

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
September 2004

Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.

Curr Med Res Opin 2003 ;19(8):707-14

McGill Centre for Studies in Aging, Verdun, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079903125002450DOI Listing
August 2004

Future directions in the treatment of Alzheimer's disease.

Authors:
Roger Bullock

Expert Opin Investig Drugs 2004 Apr;13(4):303-14

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.13.4.303 DOI Listing
April 2004

Cholinesterase inhibitors and vascular dementia: another string to their bow?

Authors:
Roger Bullock

CNS Drugs 2004 ;18(2):79-92

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00023210-200418020-00002DOI Listing
March 2004

Galantamine: use in Alzheimer's disease and related disorders.

Authors:
Roger Bullock

Expert Rev Neurother 2004 Mar;4(2):153-63

Kingshill Research Center, Department of Old Age Psychiatry, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon, SNI 4HZ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737175.4.2.153DOI Listing
March 2004

Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.

Dement Geriatr Cogn Disord 2004 13;17(1-2):29-34. Epub 2003 Oct 13.

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000074140DOI Listing
February 2004

Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales.

Dement Geriatr Cogn Disord 2003 ;16(4):276-82

HPRU Medical Research Centre, University of Surrey, Guildford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000072813DOI Listing
November 2003

Thoughts on the long-term management of Alzheimer disease.

Authors:
Roger Bullock

Alzheimer Dis Assoc Disord 2003 Jul-Sep;17 Suppl 3:S74

View Article

Download full-text PDF

Source
November 2003

Realistic expectations: the management of severe Alzheimer disease.

Alzheimer Dis Assoc Disord 2003 Jul-Sep;17 Suppl 3:S80-5

Kingshill Research Centre, Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
November 2003

Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease.

Alzheimer Dis Assoc Disord 2003 Jul-Sep;17 Suppl 3:S86-91

Department of Geriatric Medicine, Linköping University Hospital, Linköping, Sweden.

View Article

Download full-text PDF

Source
November 2003

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

Clin Ther 2003 Jun;25(6):1765-82

Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
June 2003

Increased risk of Alzheimer's disease in mothers who gave birth to children with Down's syndrome before 35 years of age.

Authors:
Roger Bullock

Evid Based Ment Health 2002 May;5(2):61

Victoria Hospital, Swindon, UK.

View Article

Download full-text PDF

Source
May 2002

Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

Int J Geriatr Psychiatry 2002 Mar;17(3):288-9

Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon SN1 4HZ, UK.

View Article

Download full-text PDF

Source
March 2002

New drugs for Alzheimer's disease and other dementias.

Authors:
Roger Bullock

Br J Psychiatry 2002 Feb;180:135-9

Department of Old Age Psychiatry and Kingshill Research Centre, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon SNI 4HZ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1192/bjp.180.2.135DOI Listing
February 2002

Treatment-Refractory Depression in the Elderly: An Audit of Primary Care Referrals to Psychiatric Services in Swindon, U.K.

Prim Care Companion J Clin Psychiatry 1999 Dec;1(6):188-190

Kingshill Research Centre, Victoria Hospital, Swindon; and the Lovemead Group Practice, Roundstone Surgery, Trowbridge, Wiltshire, United Kingdom.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC181092PMC
http://dx.doi.org/10.4088/pcc.v01n0604DOI Listing
December 1999